Search research articles
Contact Us
Filters
Showing results (171-180 of 216) with videos related to
Page
of 22
Sort By:
Journal of Pharmaceutical Sciences
|
May 1, 1976
Bumetanide: radioimmunoassay and pharmacokinetic profile in humans
W R Dixon, R L Young, A Holazo, et al.
International Journal of Peptide and Protein Research
|
October 1, 1977
Synthesis, biological activity, and tritiation of L-3, 4-dehydroproline-containing peptides
A M Felix, C T Wang, A A Liebman, et al.
The Journal of Biological Chemistry
|
July 5, 1989
Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties
J Ware, D L Diuguid, H A Liebman, et al.
Reviews of Infectious Diseases
|
July 1, 1990
Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily
T P Cooley, L M Kunches, C A Saunders, et al.
The New England Journal of Medicine
|
May 10, 1990
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial
T P Cooley, L M Kunches, C A Saunders, et al.
Journal of Thrombosis and Haemostasis : JTH
|
October 20, 2010
Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning
C O'Connell, P Razavi, M Ghalichi, et al.
Gynecologic Oncology
|
December 25, 2012
Predictive model of venous thromboembolism in endometrial cancer
Koji Matsuo, Annie A Yessaian, Yvonne G Lin, et al.
Thrombosis Research
|
May 11, 2016
OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin
C I Piatek, S T Tagawa, D Wei-Tsai, et al.
The New England Journal of Medicine
|
May 31, 1984
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
H A Liebman, B C Furie, M J Tong, et al.
Antimicrobial Agents and Chemotherapy
|
June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials
G L Drusano, G J Yuen, G Morse, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 216) with videos related to
Sort By:
Page
of 22
Journal of Pharmaceutical Sciences
|
May 1, 1976
Bumetanide: radioimmunoassay and pharmacokinetic profile in humans
W R Dixon, R L Young, A Holazo, et al.
International Journal of Peptide and Protein Research
|
October 1, 1977
Synthesis, biological activity, and tritiation of L-3, 4-dehydroproline-containing peptides
A M Felix, C T Wang, A A Liebman, et al.
The Journal of Biological Chemistry
|
July 5, 1989
Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties
J Ware, D L Diuguid, H A Liebman, et al.
Reviews of Infectious Diseases
|
July 1, 1990
Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily
T P Cooley, L M Kunches, C A Saunders, et al.
The New England Journal of Medicine
|
May 10, 1990
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial
T P Cooley, L M Kunches, C A Saunders, et al.
Journal of Thrombosis and Haemostasis : JTH
|
October 20, 2010
Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning
C O'Connell, P Razavi, M Ghalichi, et al.
Gynecologic Oncology
|
December 25, 2012
Predictive model of venous thromboembolism in endometrial cancer
Koji Matsuo, Annie A Yessaian, Yvonne G Lin, et al.
Thrombosis Research
|
May 11, 2016
OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin
C I Piatek, S T Tagawa, D Wei-Tsai, et al.
The New England Journal of Medicine
|
May 31, 1984
Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
H A Liebman, B C Furie, M J Tong, et al.
Antimicrobial Agents and Chemotherapy
|
June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials
G L Drusano, G J Yuen, G Morse, et al.
Page
of 22